Mumbai: Glenmark Pharmaceuticals announced the upcoming launch of Zanubrutinib after being approved by the drug controller in India (DCGI) in India.
Hematological malignancies, also known as blood cancers, are cancers caused by blood, bone marrow or lymphatic system.
Brucinsa, as shown in different clinical studies, deals with a critical need that does not encounter a differentiated pharmacological profile by showing high response rates and durable disease control between multiple B cell malignancies. The company said Brucinsa supports the personalized care of the flexible dose regime (once or twice a day).
Brucinsa is the first and only Bruton’s inhibitor of the first and only Bruton approved in India for the treatment of five different B cell malignancy: chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL), Waldensström Macroglobulinemia (WM), Moste Macroglobulinemia Lyplobulinemi (WM), Mote Macgroglobulinemia, Mode Macgroglobulinemia, Mode Macgroglobulinemia, Momodu, Mode Macgroglobulinemia Company, Lymphoma (MZL) and follicular lymphoma (FL) added.
